S. Tries

549 total citations
16 papers, 452 citations indexed

About

S. Tries is a scholar working on Organic Chemistry, Pharmacology and Molecular Biology. According to data from OpenAlex, S. Tries has authored 16 papers receiving a total of 452 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Organic Chemistry, 7 papers in Pharmacology and 6 papers in Molecular Biology. Recurrent topics in S. Tries's work include Inflammatory mediators and NSAID effects (7 papers), Pharmacological Effects of Natural Compounds (6 papers) and Plant Toxicity and Pharmacological Properties (4 papers). S. Tries is often cited by papers focused on Inflammatory mediators and NSAID effects (7 papers), Pharmacological Effects of Natural Compounds (6 papers) and Plant Toxicity and Pharmacological Properties (4 papers). S. Tries collaborates with scholars based in Germany, Canada and Switzerland. S. Tries's co-authors include Stefan Laufer, Julio Fernandes, Jean-Pierre Pelletier, F C Jolicoeur, Dragan Jovanović, Pascal Reboul, Johanne Martel-Pelletier, John L. Wallace, W. McKnight and William M. Abraham and has published in prestigious journals such as European Journal of Pharmacology, Inflammation Research and Pulmonary Pharmacology & Therapeutics.

In The Last Decade

S. Tries

16 papers receiving 437 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Tries Germany	12	311	123	103	90	84	16	452
Britta Gretzer Germany	8	299 1.0×	34 0.3×	43 0.4×	81 0.9×	14 0.2×	11	475
Tohru Miyazawa Japan	8	240 0.8×	95 0.8×	49 0.5×	96 1.1×	9 0.1×	13	533
Stephanie Pick Germany	6	241 0.8×	100 0.8×	54 0.5×	106 1.2×	5 0.1×	8	420
Yusaku Komoike Japan	15	301 1.0×	40 0.3×	58 0.6×	93 1.0×	5 0.1×	21	579
Ishtiaq Mahmud Japan	11	155 0.5×	18 0.1×	58 0.6×	113 1.3×	9 0.1×	23	383
Clare T. Atherton United Kingdom	4	78 0.3×	65 0.5×	33 0.3×	223 2.5×	11 0.1×	5	337
Shoko Hase Japan	5	282 0.9×	41 0.3×	45 0.4×	54 0.6×	3 0.0×	7	414
Leon Ellenbogen China	13	57 0.2×	39 0.3×	18 0.2×	199 2.2×	134 1.6×	40	493
Lee‐Yong Khil South Korea	16	209 0.7×	125 1.0×	21 0.2×	197 2.2×	5 0.1×	25	566
Gaby‐Fleur Böl Germany	10	29 0.1×	42 0.3×	59 0.6×	252 2.8×	10 0.1×	12	558

Countries citing papers authored by S. Tries

Since Specialization

Citations

This map shows the geographic impact of S. Tries's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Tries with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Tries more than expected).

Fields of papers citing papers by S. Tries

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Tries. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Tries. The network helps show where S. Tries may publish in the future.

Co-authorship network of co-authors of S. Tries

This figure shows the co-authorship network connecting the top 25 collaborators of S. Tries. A scholar is included among the top collaborators of S. Tries based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Tries. S. Tries is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Tries, S., et al.. (2002). The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflammation Research. 51(3). 135–143. 82 indexed citations

Tries, S., Stefan Laufer, Piotr Radziwon, & H.K. Breddin. (2002). Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with COX/5-LOX inhibitory activity. Inflammation Research. 51(3). 129–134. 14 indexed citations

Boileau, Christelle, Johanne Martel‐Pelletier, Patrick Netter, et al.. (2002). Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors.. PubMed. 29(7). 1446–53. 30 indexed citations

Jovanović, Dragan, Julio Fernandes, Johanne Martel-Pelletier, et al.. (2001). In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase 1 and interleukin-1? synthesis. Arthritis & Rheumatism. 44(10). 2320–2330. 85 indexed citations

Imming, Peter, et al.. (2001). Anti-inflammatory planar chiral [2.2]paracyclophaneacetic acid enantiomers. Inflammation Research. 50(7). 371–374. 4 indexed citations

Gay, R E, et al.. (2001). Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis.. PubMed. 28(9). 2060–5. 30 indexed citations

Tries, S. & Stefan Laufer. (2001). The pharmacological profile of ML3000: A new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Inflammopharmacology. 9(1-2). 113–124. 60 indexed citations

Laufer, Stefan, et al.. (1998). ChemInform Abstract: Synthesis and Evaluation of a Novel Series of Pyrrolizine Derivatives (VII) as Dual Cyclooxygenase‐1 and 5‐Lipoxygenase Inhibitors.. ChemInform. 29(5). 1 indexed citations

Abraham, William M., Stefan Laufer, & S. Tries. (1997). The Effects of ML 3000 on Antigen-induced Responses in Sheep. Pulmonary Pharmacology & Therapeutics. 10(3). 167–173. 19 indexed citations

10.

Laufer, Stefan, et al.. (1997). Synthesis and Evaluation of a Novel Series of Pyrrolizine Derivatives as Dual Cyclooxygenase‐1 and 5‐Lipoxygenase Inhibitors. Archiv der Pharmazie. 330(9-10). 307–312. 24 indexed citations

11.

Laufer, Stefan, et al.. (1995). Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4- chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid.. PubMed. 45(1). 27–32. 25 indexed citations

12.

Laufer, Stefan, et al.. (1995). General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3- dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals.. PubMed. 45(2). 159–65. 16 indexed citations

13.

Tries, S., et al.. (1995). Studies on the in vitro and in vivo genotoxicity of [2,2-dimethyl-6- (4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid.. PubMed. 45(4). 486–90. 5 indexed citations

14.

Wallace, John L., et al.. (1994). ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury. European Journal of Pharmacology. 271(2-3). 525–531. 38 indexed citations

15.

Laufer, Stefan, et al.. (1994). Gastrointestinal tolerance of [2,2-dimethyl-6-(4-chlorophenyl-7-phenyl- 2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in the rat.. PubMed. 44(12). 1329–33. 17 indexed citations

16.

Veigel, Claudia, et al.. (1991). The Influence of Oxidatively Modified Low Density Lipoprotein on Parameters of Energy Metabolism and Contractile Function of Arterial Smooth Muscle. Free Radical Research Communications. 11(6). 281–286. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact